文章名稱引用次數(shù)

• Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease43
• Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications27
• Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes24
• Diabetic retinopathy, a vascular and inflammatory disease: Therapeutic implications20
• Burden of diabetes, hyperglycaemia in China from to 2016: Findings from the 1990 to global burden of disease study18
• Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials15
• The application of simple metrics in the assessment of glycaemic variability14
• Early worsening of diabetic retinopathy after rapid improvement of blood glucose control in patients with diabetes14
• Digital diabetes: Perspectives for diabetes prevention, management and research14
• Role of myokines in the development of skeletal muscle insulin resistance and related metabolic defects in type 2 diabetes12